MeOmics Precision Medicine Ltd

MeOmics Precision Medicine Ltd focuses on pioneering advancements in psychiatric drug development through the use of patient-derived human brain cells, leveraging artificial intelligence for enhanced treatment efficacy. MeOmics Precision Medicine Ltd specializes in developing innovative psychiatric drugs. Founded in 2021 in Cardiff, UK, the company has undergone no known pivots in its business strategy. MeOmics has completed 2 deals, with its most recent funding round in February 2026, where it raised GBP 25,000 in a GRANT from the Welsh Government, bringing the total amount raised to GBP 300,000.

The company does not have reported subsidiaries, and there is no information on the founder's prior ventures. MeOmics specializes in the development of innovative psychiatric drugs by utilizing patient-derived human brain cells. Their core service lies in growing human neurons from patients’ stem cells, allowing them to measure advanced electrical activity and analyze cellular responses to various treatments. This approach aims to address the issue of psychiatric drug trial failures linked to patient diversity.

By harnessing artificial intelligence in their analysis, MeOmics seeks to predict patient responses to treatments before clinical trials, facilitating more effective drug development. Their products cater to pharmaceutical companies and research institutions globally, particularly in North America, Europe, and parts of Asia, where the demand for precision medicine in psychiatry is increasing. The revenue model for MeOmics is based on partnerships with biopharma companies and research institutions. Transactions typically involve B2B relationships where pharmaceutical firms engage MeOmics to leverage their proprietary technology and data analysis capabilities for drug development.

These partnerships may include subscription agreements for ongoing access to their proprietary platform or project-based fees for specific research collaborations. MeOmics’ services, including their methodologies, are likely priced premiumly due to their advanced capabilities and the value provided in reducing drug trial risks, positioning the company to benefit from the growing demand for tailored psychiatric treatments. In February 2026, MeOmics Precision Medicine Ltd received GBP 25,000 of grant funding from the Welsh Government, which will be utilized to advance platform development, data generation, and to hire new technical staff. The company aims to introduce new products designed to enhance their psychiatric treatment offerings while expanding into North America, Europe, and parts of Asia by late 2026.

This funding will support their initiatives to bolster their technological capabilities and product line as they strive to meet the demands of the precision medicine market.